Cervical screening in England: The past, present, and future

被引:45
|
作者
Albrow, Rebecca [2 ]
Kitchener, Henry [2 ]
Gupta, Nalini [3 ]
Desai, Mina [1 ]
机构
[1] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Cytol Ctr, Manchester Royal Infirm, Manchester M13 9WL, Lancs, England
[2] Univ Manchester, Sch Canc & Enabling Sci, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[3] Postgrad Inst Med Educ & Res, Dept Cytol & Gynaecol Pathol, Chandigarh 160012, India
关键词
cervical intraepithelial neoplasia; mass screening; vaginal smears; papillomavirus infections; RANDOMIZED CONTROLLED-TRIAL; FOLLOW-UP; CYTOLOGY; CANCER; WOMEN; TERMINOLOGY; HISTORIES; WORKING; UK;
D O I
10.1002/cncy.20203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cervical screening in England commenced in a disorganized fashion in 1964. The flaws of this approach became apparent in the mid-1980s and led to the inception of the National Health Service Cervical Screening Programme (NHSCSP). The main features of this program are its population-based registry, accessibility to all women within the screening age range, its systematic process of call and recall, national coordination, and quality assurance. Its success is in part based on its ability to evolve as evidence necessitates, and throughout the period of 2000-2010, it embarked upon a series of developments involving liquid-based cytology, which also provided the means to conduct reflex high-risk human papillomavirus (HR-HPV) testing and the potential to automate the screening process. As a result of evidence acquired since 2000, the NHSCSP is currently based on a system of primary cytology with HPV triage for low-grade abnormalities combined with cytology plus a HR-HPV test of cure for women who have received treatment for cervical intraepithelial neoplasia. Future challenges for the program will involve finding solutions to increasing screening uptake among women <30 years of agea problem that may be exacerbated when vaccinated women reach the screening age, while making plans to accommodate HPV primary screening. Cancer (Cancer Cytopathol) 2012;. (c) 2012 American Cancer Society.
引用
收藏
页码:87 / 96
页数:10
相关论文
共 50 条
  • [31] Forum (Non) Conveniens in England: Past, Present and Future.
    Day, William
    CAMBRIDGE LAW JOURNAL, 2020, 79 (01): : 189 - 191
  • [32] MYCOBACTERIUM-BOVIS IN ENGLAND AND WALES - PAST, PRESENT AND FUTURE
    HARDIE, RM
    WATSON, JM
    EPIDEMIOLOGY AND INFECTION, 1992, 109 (01): : 23 - 33
  • [33] Corporate Criminal Liability in England and Wales: Past, Present, and Future
    Wells, Celia
    CORPORATE CRIMINAL LIABILITY: EMERGENCE, CONVERGENCE, AND RISK, 2011, 9 : 91 - 112
  • [34] Tumor immunology CRISPR screening: present, past, and future
    Dong, Matthew B.
    Tang, Kaiyuan
    Zhou, Xiaoyu
    Zhou, Jingjia J.
    Chen, Sidi
    TRENDS IN CANCER, 2022, 8 (03) : 210 - 225
  • [35] CKD Screening and Surveillance in Australia: Past, Present, and Future
    Venuthurupalli, K.
    Hoy, Wendy E.
    Healy, Helen G.
    Cameron, Anne
    Fassett, Robert G.
    KIDNEY INTERNATIONAL REPORTS, 2018, 3 (01): : 36 - 46
  • [36] NEWBORN SCREENING FOR INTELLECTUAL DISABILITY: PAST, PRESENT, AND FUTURE
    Bailey, Don
    INTERNATIONAL REVIEW OF RESEARCH IN MENTAL RETARDATION, VOL 36, 2008, 36 : 1 - 25
  • [37] Lung cancer screening at the VA: Past, present and future
    Maurice, Nicholas M.
    Tanner, Nichole T.
    SEMINARS IN ONCOLOGY, 2022, 49 (3-4) : 206 - 212
  • [38] Prenatal screening for cystic fibrosis: past, present and future
    Richards, CS
    Grody, WW
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2004, 4 (01) : 49 - 62
  • [39] Progress in colorectal cancer screening: Past, present, and future
    Gray, Darrell M., II
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [40] Newborn bloodspot screening in the UK - past, present and future
    Downing, Melanie
    Pollitt, Rodney
    ANNALS OF CLINICAL BIOCHEMISTRY, 2008, 45 : 11 - 17